Brightstar Therapeutics

What Brightstar Therapeutics does

Brightstar Therapeutics is a Lexington, Kentucky-based biotechnology company founded in 2023 that develops and commercializes ophthalmic tissue products for ocular surface disease. Its core product, the BrightMEM Corneal Allograft, is a corneal allograft made from Descemet's membrane, aseptically processed from donated human corneas under FDA cGTP regulations and used in the Descemet's Membrane Anterior Keratoplasty (DMAK) procedure to treat conditions including limbal stem cell deficiency (LSCD). Brightstar was the first company to offer a long-term solution for impaired ocular healing through this product. The underlying technology is protected by a granted patent with Dr. Joshua Hou as primary inventor, and the company is leveraging the platform to build a pipeline of cell therapy products.

The company operates a B2B, physician-registration-gated sales motion in which registered ophthalmologists and cornea specialists order BrightMEM directly, supported by an eye bank partner network that supplies donor tissue and assists distribution (Saving Sight, Lions Gift of Sight, The North Carolina Eye Bank, VisionFirst). Pricing is quote-based and not publicly disclosed, consistent with specialty medical-device economics. Its customer segments are cornea specialists performing DMAK and patients with ocular surface diseases; partner channels include regional U.S. eye banks. Clinical evidence development is anchored in an NIH-funded research lab at the University of Minnesota and an ongoing registered study (NCT05909735) for LSCD, with interim data presented at the EBAA and Cornea Society Cornea and Eye Banking Forum in 2025. In March 2026, Brightstar formed a Joint Medical Advisory Board with Vital Tears spanning 11 ocular surface specialists to advance clinical innovation.

Name

Brightstar Therapeutics

Legal name

Brightstar Therapeutics

Website

https://brightstartx.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

Brightstar Therapeutics is a Lexington, Kentucky-based biotech founded in 2023 that develops the BrightMEM Corneal Allograft and a cell therapy pipeline for ocular surface diseases, serving U.S. ophthalmologists and cornea specialists through registered physician sales and an eye bank partner network.

Ownership category

akta.pro rank

Product category

Corneal Allografts

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery) (HLAHAJAK)

akta.pro secondary industries

Ophthalmic Regeneration (cornea/retina) (HLAAAGAK), Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB), Cornea, External Disease & Refractive Surgery (LASIK/PRK) (HLAKAKAF)

Keywords

• Corneal allograft products
• Ocular surface therapies
• Cell therapy pipeline
• Ophthalmic biotechnology
• Limbal stem cell treatment

Headquarters

HQ city

Lexington

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. BrightMEM Corneal Allograft Sales: Revenue generated from the sale of BrightMEM corneal allograft products to registered physicians and eye banks for surgical procedures treating ocular surface diseases including limbal stem cell deficiency (LSCD).

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Brightstar Therapeutics develops, processes, and sells the BrightMEM Corneal Allograft, an innovative allograft made from Descemet's membrane that is transplanted onto the ocular surface during Descemet's Membrane Anterior Keratoplasty (DMAK) procedures. The product is aseptically processed from donated human corneas under FDA cGTP regulations and is sold to registered ophthalmologists and eye bank partners for treatment of ocular surface diseases including limbal stem cell deficiency (LSCD). The company is also developing a pipeline of cell therapy products using patented corneal tissue processing technology.

Product overview

Brightstar Therapeutics is a biotechnology company offering a single core product—the BrightMEM Corneal Allograft—launched in 2023 as the first long-term solution for patients with impaired ocular healing. The company is also developing a pipeline of cell therapy products using patented technology for the treatment of ocular surface diseases.

Differentiator

Problem solved

Functional benefit

Brands

• BrightMEM: The BrightMEM Corneal Allograft is an innovative corneal allograft made from Descemet's membrane, used in Descemet's Membrane Anterior Keratoplasty (DMAK) procedures for treating ocular surface diseases including limbal stem cell deficiency (LSCD).

Products and services

• BrightMEM Corneal Allograft An innovative corneal allograft made from Descemet's membrane that serves as an optimized substrate for transplantation onto the ocular surface. Used in Descemet's Membrane Anterior Keratoplasty (DMAK) procedures for treating ocular surface diseases including limbal stem cell deficiency (LSCD). Aseptically processed from donated human corneas according to FDA cGTP regulations and ordered by registered ophthalmologists and eye banks.

Quantifiable outcome

• New findings support Brightstar's corneal allograft for LSCD - interim data presented at Eye Bank Association of America and Cornea Society's Cornea and Eye Banking Forum

Named customers1 record

Segments3 records

Ideal customer profiles2 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Vital TearscoreStrategic or Co-development Partner · 4 March 2026Vital Tears and Brightstar Therapeutics announced formation of a Joint Medical Advisory Board to advance clinical innovation in ocular surface care. This partnership combines both companies' expertise in ocular surface disease treatment and dry eye disease solutions.
• Aniridia Foundation InternationalminorStrategic or Co-development PartnerAcknowledged for support of the clinical study 'Treatment of Limbal Stem Cell Deficiency With Descemet's Membrane' listed on ClinicalTrials.gov (NCT05909735).
• Saving SightcoreStrategic or Co-development PartnerCEO Tony Bavuso stated Brightstar has potential to greatly advance corneal treatments and allow for more corneal tissue to be utilized, resulting in more people receiving the gift of sight. Saving Sight is a key eye bank partner.
• Lions Gift of SightcoreStrategic or Co-development PartnerDr. Joshua Hou serves as Medical Director for Lions Gift of Sight eye bank, facilitating collaboration on corneal tissue processing and research initiatives.
• Eye Bank Association of America (EBAA)coreStrategic or Co-development PartnerDr. Hou serves as Chair of the Scientific Programs Committee of EBAA. Company acknowledges EBAA support and participates in Cornea and Eye Banking Forum events.
• Cornea SocietyminorStrategic or Co-development PartnerCollaborative partnership through joint presentation of clinical findings at the Cornea and Eye Banking Forum co-hosted with Eye Bank Association of America.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Eversight: Large U.S. eye bank providing donor corneal tissue and ocular research services. Comparable to Brightstar as a corneal tissue source and distributor in the same surgeon-driven U.S. market.
• CorneaGen: Leading U.S. provider of corneal tissue and ocular surgical solutions for eye banks and surgeons. Directly comparable to Brightstar because both distribute corneal allografts through U.S. eye bank networks to cornea specialists for transplantation procedures.
• TissueTech (Bio-Tissue): Commercial-stage regenerative medicine company focused on ocular surface and wound healing using amniotic membrane-based products (e.g., AmnioGraft, Prokera). Closely comparable to Brightstar in addressing ocular surface disease with biological allograft substrates sold to ophthalmologists.
• KeraLink International: Non-profit eye bank network recovering and distributing corneal tissue for transplantation. Directly comparable as a corneal tissue supplier serving the same surgeon base and procedural indications targeted by BrightMEM.
• SightLife: Eye bank and corneal tissue provider with global programs to eliminate corneal blindness. Comparable to Brightstar as a corneal tissue organization whose former leaders (e.g., at CorneaGen) overlap with Brightstar's management team.
• Lions Gift of Sight: Minnesota-based eye bank recovering, processing, and distributing corneal tissue. Directly comparable as both a partner and a peer eye bank competing for surgeon relationships in the U.S. corneal tissue market.

Broad incumbents

• Santen Pharmaceutical: Global specialty ophthalmology company with a broad portfolio of pharmaceuticals and devices across multiple ocular indications. Comparable as a large incumbent addressing ocular surface and corneal disease with greater resources and commercial scale.
• Dompé: Global biopharmaceutical company with a significant ophthalmology franchise focused on rare eye diseases and ocular surface conditions. Comparable as a broader ophthalmic therapeutics player addressing overlapping indications.

Emerging players

• Kala Pharmaceuticals: Specialty ophthalmic company developing therapies for ocular surface and rare eye diseases. Comparable as a similarly staged ophthalmic therapeutics player focused on underserved ocular conditions.
• Eyevance Pharmaceuticals: U.S. ophthalmic specialty company commercializing therapeutics for ocular surface and anterior segment conditions. Comparable as a similarly scaled ophthalmic player targeting the same prescribing specialists as Brightstar.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Brightstar Therapeutics